Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lnc-CAF antisense oligonucleotide
- Development stage
- Preclinical
- Lead developer
- Sir Run-Run Shaw Hospital
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
lnc-CAF antisense oligonucleotide is an antisense oligonucleotide (ASO) designed to target and silence the long non-coding RNA lnc-CAF (also known as FLJ22447). lnc-CAF is a cancer-associated fibroblast (CAF)-derived exosomal long non-coding RNA that is upregulated in the tumor microenvironment of various cancers, including prostate cancer and oral squamous cell carcinoma. Mechanistically, lnc-CAF acts as a scaffold connecting BRD4 with CHD1, facilitating chromatin looping between enhancers and interferon-regulatory promoters, which suppresses innate immune signaling and promotes pro-metastatic transcriptional programs. ASO-mediated knockdown of lnc-CAF inhibits this pathway, restoring interferon pathway activity and reducing tumor invasion and metastatic burden.
- Other names
- FLJ22447 ASOFLJ-22447 ASOFLJ 22447 ASOFLJ22447 antisense oligonucleotideFLJ-22447 antisense oligonucleotideFLJ 22447 antisense oligonucleotidelnc-CAF ASO
Beyond the preview
Go deeper on lnc-CAF antisense oligonucleotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lnc-CAF antisense oligonucleotide.